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Abstract
Background: Dengue virus infected patients have high plasminogen activator inhibitor type I (PAI-1) plasma
concentrations. Whether the insertion/deletion (4G/5G) polymorphism in the promotor region of the PAI-1 gene
is associated with increased PAI-1 plasma concentrations and with death from dengue is unknown. We, therefore,
investigated the relationship between the 4G/5G polymorphism and PAI-1 plasma concentrations in dengue
patients and risk of death from dengue.
Methods: A total of 194 patients admitted to the Dr. Kariadi Hospital in Semarang, Indonesia, with clinical
suspected severe dengue virus infection were enrolled. Blood samples were obtained on day of admission, days
1, 2 and 7 after admission and at a 1-month follow-up visit. Plasma concentrations of PAI-1 were measured using
a sandwich ELISA kit. The PAI-1 4G/5G polymorphism was typed by allele-specific PCR analysis.
Results: Concentrations of PAI-1 on admission and peak values of PAI-1 during admission were higher than the
values measured in healthy controls. Survival was significantly worse in patients with PAI-1 concentrations in the
highest tertile (at admission: OR 4.7 [95% CI 0.9–23.8], peak value during admission: OR 6.3 [95%CI 1.3–30.8]).
No association was found between the PAI-1 4G/5G polymorphism, and PAI-1 plasma concentrations, dengue
disease severity and mortality from dengue.
Conclusion:  These data suggest that the 4G/5G polymorphism has no significant influence on PAI-1
concentrations in dengue virus infected patients and is not associated with the risk of death from dengue. Other
factors contributing to the variability of PAI-1 plasma concentrations in patients with dengue need to be explored.
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Background
Dengue is the most prevalent viral disease transmitted by
arthropod vectors worldwide [1]. An estimated 50–100
million cases of dengue fever and 500.000 cases of dengue
haemorrhagic fever resulting in around 24.000 deaths
occur annually depending on epidemic activity [1,2]. At
present, almost 30% of the world population is at risk for
dengue virus infection and it is expected that this number
will increase substantially as transmission spreads to
other yet unaffected geographic regions [3]. The viruses
are transmitted to humans through infected mosquitoes,
and may induce clinical manifestations ranging from a
mild, uncomplicated febrile illness to the more severe
dengue haemorrhagic fever and dengue shock syndrome.
Increased vascular permeability is thought to be central in
the pathogenesis of dengue haemorrhagic fever and den-
gue shock syndrome, since it results in the loss of plasma
from the vascular compartment, which may give rise to
shock in severe cases. Bleeding manifestations are
believed to result from thrombocytopenia and thrombo-
cytopathia, but increasing evidence suggests an important
role for other abnormalities in the coagulation and fibri-
nolytic systems [4].
Nearly all patients suffering from dengue haemorrhagic
fever show some evidence of a deranged coagulation sys-
tem, but coagulation abnormalities are most marked in
dengue shock syndrome patients [5]. The activity of the
fibrinolytic system is amongst others regulated by plas-
minogen activator inhibitor type I (PAI-1), of which levels
may greatly increase during acute phase reactions. Indeed,
levels of PAI-1 are high in particular in dengue shock syn-
drome patients with an adverse clinical outcome [6,7]. A
single base pair insertion/deletion (4G/5G) polymor-
phism in the promotor region of the PAI-1 gene has been
associated with increased plasma concentrations of PAI-1
and with the development of shock and death after infec-
tion with Neisseria meningitides [8,9]. We therefore
investigated whether in dengue virus infected patients
increased PAI-1 levels are associated with a greater risk of
death from dengue and whether the 4G/4G genotype con-
tributes to these higher levels.
Methods
Patients were selected from two observational studies con-
ducted in the Dr. Kariadi Hospital in Semarang, Indone-
sia. In the first study, performed from 1996 to 1997 at the
paediatric intensive care unit, a total of 50 patients with a
clinical diagnosis of suspected dengue shock syndrome
were studied. Blood samples were obtained from these
patients on day of admission and on days 1, 2 and 7 after
admission. The study protocol and the results of the meas-
urement of PAI-1 plasma levels have been described pre-
viously [6]. The second study was performed from 2001 to
2003 at the paediatric intensive care unit and the paediat-
ric ward. Patients, aged 3 to 14 years, admitted to the hos-
pital with a clinical diagnosis of suspected dengue shock
syndrome or with a clinical diagnosis of suspected dengue
haemorrhagic fever were included. Demographic data,
medical history, physical examination findings and subse-
quent progress for each patient were recorded on a stand-
ard data form. Blood samples were obtained on day of
admission, days 1, 2 and 7 after admission and at a 1-
month follow-up visit. A formal classification, according
to WHO criteria [2], using all available clinical and labo-
ratory data, was done after completion of both studies. If
dengue virus infected patients did not meet the criteria for
dengue haemorrhagic fever or dengue shock syndrome,
they were considered to suffer from dengue fever. The con-
trols were healthy school-aged children who had no his-
tory of dengue haemorrhagic fever or dengue shock
syndrome and originated from the same geographical area
as the cases.
All blood samples were centrifuged within 1–2 hours after
retrieval at 15°C for 20 minutes at 1600*g. Plasma was
separated, stored at -80°C and assayed batch-wise in the
Netherlands after transportation on dry ice. Since coagu-
lation test results are affected by poor sample quality, only
test results of samples with no visible haemolysis or clot
formation were included in this analysis. Plasma concen-
trations of PAI-1 were measured using two separate assays.
A sandwich ELISA kit that has been described by de Boer
et al [10], was used in the 1996–1997 study. In the second
study a commercially available sandwich ELISA kit (Imu-
lyse, Biopool, Sweden) was used. Genomic DNA from
patients was prepared either from EDTA whole blood by
means of a salting out method as described elsewhere or
in case only plasma samples were available with use of the
Invisorb® Spin Cell Mini Kit (Invitek GmbH, Berlin, Ger-
many) [11]. The insertion/deletion (4G/5G) polymor-
phism in the promotor region of the PAI-1 gene was typed
by allele-specific PCR and RFLP analysis [11]. The ethics
committee of the Dr. Kariadi Hospital approved all clini-
cal and laboratory aspects of both studies. Blood samples
were taken from patients and controls provided that a par-
ent or legal guardian gave informed consent.
Paired blood samples from both studies were tested for
serologic evidence of acute dengue infection. A commer-
cially available capture and indirect ELISA (Focus Tech-
nologies, Cypress, Calif., USA) was used for the detection
of dengue virus specific IgM and IgG antibodies respec-
tively. This was performed according to the procedures
described by the manufacturer [12]. For some patients, a
definitive serodiagnosis was not possible because no con-
valescent sample was obtained. Detection of dengue anti-
gen and RNA was attempted in these cases using a dot blot
immunoassay and a dengue serotype specific revere tran-
scriptase PCR respectively [13]. Patients with serologicThrombosis Journal 2005, 3:17 http://www.thrombosisjournal.com/content/3/1/17
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evidence of acute dengue infection, a positive dot blot
and/or positive PCR were considered to have confirmed
dengue virus infection. Those with definite negative serol-
ogy and/or a well-substantiated alternative clinical diag-
nosis were classified as not dengue. In the absence of a
well-substantiated alternative clinical diagnosis and with
inconclusive serology patients were classified as indeter-
minate.
Categorical data are expressed as numbers and frequen-
cies, and were compared by means of χ2 analysis. Contin-
uous data are expressed as medians with corresponding
interquartile ranges and were compared by means of the
Kruskal Wallis test. Since PAI-1 plasma levels were meas-
ured using two different assays, the nonparametric regres-
sion procedure of Passing and Bablok was used to
compare these two methods and to validate recalculation
of one of the datasets to pool the data [14]. For this pur-
pose, 39 samples were analysed with both assays. The
Passing and Bablok regression equation resulting from
this comparison is given in the Results section, together
with the 95% confidence intervals for the estimates of
slope and intercept. PAI-1 plasma levels obtained from
the 1996–1997 cohort were converted using the regres-
sion equation. We subsequently divided PAI-1 plasma lev-
els on admission and peak PAI-1 plasma levels during
admission into tertiles of similar size. Odds ratios and the
corresponding 95% confidence intervals (95% CI) were
estimated by cross-tabulation using the lowest tertile as
reference category. To determine the association between
PAI-1 concentration and mortality independent of age,
sex, year project and plasminogen activator inhhibitor-1
polymorphism, we used logistic regression analyses. A P-
value ≤ 0.05 was considered to indicate statistical signifi-
cance. Analyses were performed using SPSS 11.0.1.
Method comparison was performed using Analyse-it Clin-
ical Laboratory statistics module version 1.62 for Micro-
soft Excel.
Results
Of 233 enrolled patients with suspected dengue haemor-
rhagic fever or dengue shock syndrome admitted to the
paediatric intensive care unit and the paediatric ward of
the Dr. Kariadi Hospital, 202 (87%) were confirmed to
have acute dengue, 3 (1%) were categorised as definitely
not dengue and 28 (12%) as indeterminate. When a for-
mal classification using the criteria set by the WHO was
performed, 106 (52%) were classified as having dengue
shock syndrome, 76 (38%) as having dengue haemor-
rhagic fever and 20 (10%) as having dengue fever. Nine-
teen of 202 patients with confirmed dengue (9%) died
during follow up.
Genomic DNA was obtained from 194 patients. The
remaining patients could not be typed because of insuffi-
cient volume of blood left or low yield of DNA. Clinical
features and basic laboratory investigations on admission
of the 194 patients are summarised in Table 1. The num-
bers of 4G/4G, 4G/5G and 5G/5G PAI-1 genotypes
among patients in relation to mortality are summarised in
Table 2. Of 192 control samples tested, 45 patients (23%)
were 4G/4G homozygous, 83 (43%) were 4G/5G hetero-
zygous, and 64 (33%) were 5G/5G homozygous. The fre-
quencies of the PAI-1 promoter genotypes 4G/4G, 4G/5G,
and 5G/5G did not differ significantly between the 1996–
1997 project, the 2001–2003 project and the control
group (P = 0.520). The proportion of deaths among
patients with the 4G/4G, 4G/5G and 5G/5G genotype did
not differ significantly (1996–1997 project: P = 0.979;
2001–2003 project: P = 0.986; two projects combined: P
= 0.781). The genotype frequencies among patients with
respect to final clinical diagnosis according to the criteria
set by the WHO are summarised in Table 3. Results indi-
Table 1: Clinical characteristics and laboratory findings
Characteristic
Age, median (IQR), years 6 (4–10)
Male sex, n (%) 92 (47)
Duration of symptoms, median (range), days 4 (1–7)
Systolic blood pressure, median (IQR), mmHg 90 (80–100)
Pulse pressure <20 mmHg, n (%) 22 (11)
Spontaneous bleeding, n (%) 118 (62)
Haematocrit, median (IQR), % 41 (36–45)
Platelet count, median (IQR), cells *103/mm3 58 (37–85)
° IQR denotes 25th and 75th interquartile range, n denotes number 
of patients.
Table 2: Clinical outcome of dengue virus infected patients classified by PAI-1 genotype
1996–1997 2001–2003
Genotype All patients Survivors Non-survivors All patients Survivors Non-survivors
G4/G4 8 (18%) 6 (14%) 2 (5%) 33 (22%) 32 (21%) 1 (1%)
G4/G5 15 (34%) 11 (25%) 4 (9%) 62 (41%) 60 (40%) 2 (1%)
G5/G5 21 (48%) 15 (34%) 6 (14%) 55 (37%) 53 (35%) 2 (1%)
Total 44 (100%) 32 (73%) 12 (27%) 150 (100%) 145 (97%) 5 (3%)Thrombosis Journal 2005, 3:17 http://www.thrombosisjournal.com/content/3/1/17
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cate that the PAI-1 promoter genotypes are not associated
with dengue disease severity (P = 0.508).
PAI-1 plasma levels were measured in 124 patients from
whom sufficient frozen plasma samples was available
with the use of two separate ELISA's. Thirty-nine random
plasma samples were used for the comparison of the two
assays. PAI-1 level measurements are known to be
dependent on the assay employed, since not all antibod-
ies used have the same specificity with respect to the vari-
ous molecular forms of PAI-1 in blood (active PAI-1, PAI-
1 complexed with vitronectin, inactive or latent PAI-1 and
PAI-1 complexed with its target proteases tissue-type and
urokinase-type plasminogen activator) [15]. Passing &
Bablok regression analysis (Figure 1), however, clearly
showed that the two assays employed in this study have a
straightforward linear relationship between their out-
comes. This allowed us to convert the PAI-1 levels meas-
ured in the 1996–1997 cohort to levels that would have
been obtained with the assay used in the second cohort,
using the Passing and Bablok regression equation (an
intercept of -7.42 ng/ml (95% CI, -16.39 to -3.24 ng/ml)
and slope of 0.35 (95% CI, 0.30 to 0.42)). Concentrations
of PAI-1 on admission (71 ng/ml [42–118]) and peak val-
ues during admission (96 ng/ml [64–199]) were higher
than the concentrations measured in the healthy control
group (30–60 ng/ml). Patients included in the 2001–
2003 project and diagnosed with DSS had higher PAI-1
plasma levels on admission (P = 0.002) and during
admission (P < 0.001) than those diagnosed with DF or
DHF (Table 4). However, no statistical significant differ-
ence was present between patients with different dengue
disease severities when both projects were combined
(PAI-1 plasma levels on admission: P = 0.212 and during
admission: P = 0.089). Survival was significantly worse in
patients with PAI-1 concentrations in the highest tertile
(Table 5). As shown by multiple logistic regression analy-
sis, the odds ratio for the risk of death – adjusted for age,
sex, year project and plasminogen activator inhibitor-1
genotype – of PAI-1 levels at admission in the highest ter-
Table 3: Dengue disease severity and PAI-1 genotype
Genotype DF DHF DSS
G4/G4 6 (3%) 13 (7%) 22 (11%)
G4/G5 6 (3%) 35 (18%) 36 (19%)
G5/G5 8 (4%) 27 (14%) 41 (21%)
Total 20 (10%) 75 (39%) 99 (51%)
Relation between PAI-1 plasma concentrations and PAI-1 genotype in dengue virus infected patients Figure 2
Relation between PAI-1 plasma concentrations and PAI-1 genotype in dengue virus infected patients. Box-and-
whisker plots of PAI-1 plasma concentrations on admission (A.) and peak values during admission (B.). The central line in the 
box plot represents the median, the boxed areas represent the interquartile ranges. Whiskers at the ends of the box show the 
distance from the end of the box to the largest and smallest observed values that are less than 1.5 box lengths from either end 
of the box.
G4 G4G5 G5
PAI-1 polymorphism
0
500
1000
1500
P
A
I
-
1
(
n
g
/
m
l
)
A.
G4 G4G5 G5
PAI-1 polymorphism
0
500
1000
1500
P
A
I
-
1
(
n
g
/
m
l
)
B.Thrombosis Journal 2005, 3:17 http://www.thrombosisjournal.com/content/3/1/17
Page 5 of 8
(page number not for citation purposes)
tile was 7.57 (95%CI, 1.16–49.30). The adjusted odds
ratio for the risk of death of peak PAI-1 levels during
admission in the highest tertile was 7.41 (95%CI, 1.30–
42.26). Figure 2 illustrates the relation between PAI-1
plasma concentrations and the PAI-1 genotypes. Differ-
ences were not statistically significant (values at admis-
sion: P = 0.919; peak values during admission: P = 0.470).
Discussion
This study was undertaken to investigate the relationship
between PAI-1 plasma concentrations and clinical out-
come of dengue virus infections, and to establish whether
PAI-1 plasma concentrations in dengue virus infected
individuals are associated with the 4G/5G promotor pol-
ymorphism in the PAI-1 gene. We and others have previ-
ously found increased PAI-1 plasma concentrations in
patients with severe dengue in particular in those with a
poor clinical outcome [5,7]. Since a genetic predisposition
to produce high PAI-1 plasma concentrations appears to
be associated with poor clinical outcome in Neisseria
meningitides infections [8,9], we hypothesised that den-
gue virus infected individuals carrying the 4G/4G geno-
type have higher PAI-1 plasma concentrations and are
therefore at increased risk of death. Consistent with previ-
ous studies, we found increased PAI-1 concentrations in
dengue virus infected individuals. However, PAI-1 plasma
concentrations were not related to dengue disease sever-
ity, but were significantly associated with death from den-
gue. No significant association between PAI-1 plasma
concentrations and carriage of the 4G/4G genotype was
observed. The frequencies of the three genotypes between
survivors and non-survivors, and between patients with
different disease severities were not different. These find-
ings suggest that increased PAI-1 plasma concentrations,
and dengue disease severity and mortality are not depend-
ent on the 4G polymorphism in the PAI-1 gene in this
population.
An increased risk of death in dengue virus infected
patients with high PAI-1 plasma concentrations adds to
findings of PAI-1 levels being able to predict lethality in
patients with bacterial sepsis in a very sensitive way [16-
20]. One of the primary roles of PAI-1 in vivo is to inhibit
tissue-type plasminogen activator, the major proteolytic
activator of plasminogen [21,22]. By inhibiting fibrino-
lytic activity, increased PAI-1 concentrations may contrib-
ute to a procoagulant state leading to an increased
deposition of fibrin and formation of microthrombi with
subsequent multiorgan failure and death. A variety of
cells, including endothelial cells, hepatocytes and plate-
lets, synthesize and secrete PAI-1 in response to inflam-
matory stimuli such as interleukin-1 and tumour necrosis
factor [10,22-24]. The release of these inflammatory
mediators by monocytes and T lymphocytes activated by
dengue virus may well contribute to the over-production
of this inhibitor of fibrinolysis [25-27]. Dawson and col-
leagues showed that the common insertion/deletion (4G/
5G) polymorphism in the promotor region of the PAI-1
gene affects the response of the gene to acute phase stim-
uli [23]. The 4G allele produced six times more mRNA
than the 5G allele in response to interleukin-1 [23]. Eriks-
son and colleagues, however, were unable to reproduce
these findings and based on their study results they con-
cluded that the insertion/deletion (4G/5G) polymor-
phism is not related to an allele-specific response to
interleukin-1 [28]. Instead, they found that the insertion/
deletion (4G/5G) polymorphism influences basal PAI-1
transcription only [28].
Apparently other underlying mechanisms not related to
the 4G/5G polymorphism must be involved in the
increase in PAI-1 levels found in dengue virus infected
individuals. This might include clearance impairment
rather than or in addition to stimulation of synthesis. It is
interesting to note that PAI-1 is cleared from the circula-
tion by the liver [29]. Indeed in patients with severe liver
disease, PAI-1 has been shown to be increased as a result
of a decrease in hepatic clearance [30,31]. Since hepatic
dysfunction is a relatively common finding in severe den-
gue virus infections, it is possible that a less efficient clear-
Comparison of two PAI-1 assays Figure 1
Comparison of two PAI-1 assays. Comparison of PAI-1 
plasma levels obtained by a Biopool assay and an assay previ-
ously described by de Boer and colleagues [10]). The Passing 
& Bablok regression equation is: y = 0,3505x - 7,4227 ng/ml; 
n = 39. Solid line, regression line; dashed lines, 95% CI for the 
regression line.
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ance contributes to increased PAI-1 levels in dengue virus
infected individuals [32-34]. Previous studies investigated
factors that could potentially influence PAI-1 levels,
including environmental factors, metabolic determinants,
ethnicity and a variety of other polymorphisms within the
PAI-1 gene [35-38]. It remains unclear whether and to
what extent these factors contribute to the variability in
PAI-1 levels in dengue virus infected individuals. Previ-
ously studied individuals were either healthy, were
patients with coronary artery disease, or were patients
with diabetes mellitus. Clearly these study populations
cannot be compared to patients suffering from a severe
infectious disease that is characterised by an overwhelm-
ing inflammatory response.
Several potential limitations of the present study should
be noted. The 1996–1997 cohort was characterized with a
high mortality rate of 27%. Although the exact reason for
this high mortality remains to be determined, it is likely
that it results from a combination of factors. Our study
was performed in a Tertiary Hospital that serves a large
part of Middle-Java. Patients may travel long distances to
be treated in this hospital and it could well be that they are
presented late in the course of disease. Initial fluid resus-
citation according to WHO guidelines is generally insuffi-
cient in these cases and patients usually end up in
profound shock. Despite admission at the Pediatric Inten-
sive Care Unit mortality rate is high. In addition, the
1996–1997 rainy season was characterised by high num-
bers of patients admitted to hospitals because of DHF/
DSS and high number of non-survivors. It is believed that
an unusually virulent virus circulated that year although
microbiological sampling could not be performed at that
time because of limited resources.
Study size is an important issue in the establishment of an
association between the insertion/deletion (4G/5G) poly-
morphism in the PAI-1 gene and clinical outcome. Her-
mans and colleagues previously found an association
between the homozygous 4G deletion polymorphism and
mortality from Neisseria meningitides infection among
129 patients from two different cohort groups [8]. This
association was also observed when the largest of the two
cohort groups was studied separately, but was not seen in
the smallest group in which only 37 patients were
included. In order to obtain a sufficient number of
patients, we therefore decided to combine the results of
two different projects. This decision was based on the fact
that these two projects included patients with the same
ethnic background, used similar trial procedures and
applied uniform diagnostic and clinical management pro-
cedures. Although mortality rates between the 1996–1997
cohort and the 2001–2003 cohort differed considerably,
one must realise that in the 1996–1997 cohort only DSS
Table 4: Relation between PAI-1 plasma levels and disease severity°
Project PAI-1 DF DHF DSS
(ng/ml) Median (IQR) Median (IQR) Median (IQR)
1996–1997¶ Admission - - 56.7 (33.0–130.2)
Peak values - - 91.6 (37.7–343.6)
2001–2003 Admission 77.0 (69.0–99.0) 60.0 (42.3–82.5) 107.0 (52.0–670.0)
Peak values 82.0 (69.0–129.0) 78 (59.3–118.3) 264.0 (117.0–844.0)
Total Admission 77.0 (69.0–99.0) 60.0 (42.3–82.5) 87.0 (35.0–180.8)
Peak values 82.0 (69.0–129.0) 78 (59.3–118.3) 130.7 (53.7–531.1)
° IQR denotes 25th and 75th interquartile range.
¶ Only DSS patients were included in the 1996 project.
Table 5: Mortality risk for plasminogen activator-1 plasma levels.*
PAI-1 ng/ml Number of patients Number of deaths OR (95% CI) ORadj (95% CI)°
Value at admission <50 41 2 1 1
50–94 40 3 1.6 (0.3–10.0) 3.3 (0.4–25.0)
>94 41 8 4.7 (0.9–23.8) 7.6 (1.2–49.3)
Maximum value during 
admission
< 7 2 4 1 211
72–151 42 3 1.5 (0.2–9.5) 2.1 (0.2–18.2)
>151 41 10 6.3 (1.3–30.8) 7.4 (1.3–42.3)
* CI, denotes confidence interval; OR, denotes odds ratio; ORadj, denotes adjusted odds ratio
° Risk of death adjusted for age, sex, year project and plasminogen activator inhhibitor-1 polymorphism. Lowest tertile was used as reference 
category.Thrombosis Journal 2005, 3:17 http://www.thrombosisjournal.com/content/3/1/17
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patients were included. In the 2001–2003 cohort also
included patients who had no evidence of circulatory fail-
ure were included. Mortality rate among DSS patients
included in the 2001–2003 cohort was 18%. Our findings
of similar frequencies of the PAI-1 genotypes within the
1996–1997 project and the 2001–2003 project supports
our decision to combine both groups.
In conclusion, this study demonstrates that high PAI-1
plasma levels are associated with an increased risk of
death from dengue without the 4G/5G polymorphism in
the promotor of the gene for PAI-1 playing a role. Addi-
tional studies are needed to explore the possibility of
other polymorphisms within the PAI-1 gene and factors,
like ethnicity or environmental factors, contributing to
the variability of PAI-1 plasma concentrations in patients
with dengue.
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